Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Replimune's total debt was $99.77M at Sep 30, 2026. For fiscal 2026 it was $83.31M, up 79.6% from the year before. The highest annual figure on record is $83.31M in fiscal 2026.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $83.31M | +79.6% |
| FY2025 | Mar 31, 2025 | $46.38M | +3.5% |
| FY2024 | Mar 31, 2024 | $44.81M | +56.4% |
| FY2023 | Mar 31, 2023 | $28.65M | – |
| FY2022 | Mar 31, 2022 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $99.77M | +111.3% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $84.11M | +79.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $83.31M | +79.6% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $47.63M | +3.6% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $47.21M | +3.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $46.79M | +3.5% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $46.38M | +3.5% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $45.96M | +60.4% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $45.57M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $45.19M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $44.81M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $28.65M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $0 | – |
See a number that looks wrong?